CLINICAL TRIAL

PASS

Retinal RED

Observational

A Post-Authorization, Multicenter, Multinational, Longitudinal,Observational Safety Registry Study for Patients Treated withVoretigene Neparvovec

Rare Eye Disease concerned by the trial :
Retinitis pigmentosa

Status of the trial : Active, not recruiting

Orphan drug recognition : No

Inclusion criteria : Plan to receive or have received voretigen neparvovec in at least one eye.

Exclusion criteria : Patient who did not receive voretigen neparvovec in at least one eye.

Inclusion opening date : 20/12/2019

Inclusion closing date (previsional) : 01/12/2029

Children ☑

Adults ☑

Within ERN-EYE members

Location of the trial :

CHNO des XV XX - Centre Hospitalier National d'Ophtalmologie
28 rue de Charenton
75557 Paris Cedex 12
France

Contact details



Principal investigator name :
Dr Saddek Mohand-Saïd
Pr Isabelle Audo
Pr José Alain-Sahel

Other investigators :
None

Funder type : Industry